KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Operating Income (2016 - 2025)

Neogenomics (NEO) has disclosed Operating Income for 16 consecutive years, with -$13.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 27.1% year-over-year to -$13.4 million, compared with a TTM value of -$115.9 million through Dec 2025, down 25.81%, and an annual FY2025 reading of -$115.9 million, down 25.81% over the prior year.
  • Operating Income was -$13.4 million for Q4 2025 at Neogenomics, up from -$27.0 million in the prior quarter.
  • Across five years, Operating Income topped out at -$13.4 million in Q4 2025 and bottomed at -$52.0 million in Q1 2022.
  • Average Operating Income over 5 years is -$29.6 million, with a median of -$27.4 million recorded in 2025.
  • The sharpest move saw Operating Income crashed 950.57% in 2021, then skyrocketed 38.76% in 2023.
  • Year by year, Operating Income stood at -$41.6 million in 2021, then soared by 36.53% to -$26.4 million in 2022, then rose by 29.6% to -$18.6 million in 2023, then rose by 0.93% to -$18.4 million in 2024, then rose by 27.1% to -$13.4 million in 2025.
  • Business Quant data shows Operating Income for NEO at -$13.4 million in Q4 2025, -$27.0 million in Q3 2025, and -$47.6 million in Q2 2025.